RPTX
Income statement / Annual
Last year (2023), Repare Therapeutics Inc.'s total revenue was $51.13 M,
a decrease of 61.21% from the previous year.
In 2023, Repare Therapeutics Inc.'s net income was -$93.80 M.
See Repare Therapeutics Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$51.13 M
|
$131.83 M
|
$7.60 M
|
$135,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$131.20 M |
$4.18 M |
$3.34 M |
$1.79 M |
$968,000.00 |
$407,000.00 |
$102,000.00 |
| Gross Profit |
-$80.07 M |
$127.65 M |
$4.26 M |
-$1.65 M |
-$968,000.00 |
-$407,000.00 |
-$102,000.00 |
| Gross Profit Ratio |
-1.57 |
0.97 |
0.56 |
-12.24 |
0 |
0 |
0 |
| Research and Development
Expenses |
$133.59 M
|
$119.07 M
|
$90.05 M
|
$40.09 M
|
$21.00 M
|
$9.91 M
|
$4.40 M
|
| General & Administrative
Expenses |
$33.76 M
|
$32.56 M
|
$26.21 M
|
$14.35 M
|
$5.38 M
|
$2.91 M
|
$1.77 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$33.76 M
|
$32.56 M
|
$26.21 M
|
$14.35 M
|
$5.38 M
|
$2.91 M
|
$1.77 M
|
| Other Expenses |
$0.00 |
-$43,000.00 |
-$41,000.00 |
-$16,000.00 |
-$1.36 M |
-$1.14 M |
-$1.47 M |
| Operating Expenses |
$167.36 M |
$151.63 M |
$116.26 M |
$54.44 M |
$26.38 M |
$12.82 M |
$6.18 M |
| Cost And Expenses |
$167.36 M |
$151.63 M |
$116.26 M |
$54.44 M |
$26.38 M |
$12.82 M |
$6.18 M |
| Interest Income |
$13.33 M |
$5.63 M |
$259,000.00 |
$240,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.95 M
|
$4.18 M
|
$3.34 M
|
$1.79 M
|
$968,000.00
|
$407,000.00
|
$102,000.00
|
| EBITDA |
-$114.27 M
|
-$17.82 M
|
-$107.19 M
|
-$53.41 M
|
-$25.49 M
|
-$13.51 M
|
-$7.53 M
|
| EBITDA Ratio |
-2.23 |
-0.15 |
-14.28 |
-397.32 |
0 |
0 |
0 |
| Operating Income Ratio
|
-2.27
|
-0.15
|
-14.3
|
-402.24
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$13.05 M
|
$5.90 M
|
$74,000.00
|
-$440,000.00
|
-$644,000.00
|
-$1.43 M
|
-$1.62 M
|
| Income Before Tax |
-$103.18 M |
-$13.90 M |
-$108.59 M |
-$54.74 M |
-$27.02 M |
-$14.25 M |
-$7.80 M |
| Income Before Tax Ratio
|
-2.02
|
-0.11
|
-14.29
|
-405.5
|
0
|
0
|
0
|
| Income Tax Expense |
-$9.38 M |
$15.15 M |
-$1.68 M |
-$1.33 M |
$195,000.00 |
$35,000.00 |
$147,000.00 |
| Net Income |
-$93.80 M |
-$29.05 M |
-$106.91 M |
-$53.42 M |
-$27.22 M |
-$14.28 M |
-$7.80 M |
| Net Income Ratio |
-1.83 |
-0.22 |
-14.07 |
-395.68 |
0 |
0 |
0 |
| EPS |
-2.23 |
-0.69 |
-2.83 |
-1.45 |
-0.74 |
-0.9 |
-0.49 |
| EPS Diluted |
-2.23 |
-0.69 |
-2.83 |
-1.45 |
-0.74 |
-0.9 |
-0.49 |
| Weighted Average Shares
Out |
$42.09 M
|
$41.92 M
|
$37.82 M
|
$36.90 M
|
$36.67 M
|
$15.79 M
|
$15.79 M
|
| Weighted Average Shares
Out Diluted |
$42.09 M
|
$41.92 M
|
$37.82 M
|
$36.90 M
|
$36.67 M
|
$15.79 M
|
$15.79 M
|
| Link |
|
|
|
|
|
|
|
